CRP and infection: The clinical success rate was assessed by the absence of recurrent infections (89.3%), microbiological eradication of pathogens (82.3%), and a significant reduction in inflammatory parameters (C-reactive protein, CRP: 88.1%; procalcitonin, PCT: 98.9%).